Nodality, Inc. Appoints Laura Brege as Chief Executive Officer
Published: Sep 24, 2012
Michael Goldberg, Executive Chairman of Nodality’s Board of Directors, said, “We are very pleased to have Laura as the new CEO of Nodality. Laura’s extensive strategic, commercial, financial and operating experiences within biotechnology companies at various stages of growth make her an excellent choice to lead the team and company.”
Ms. Brege stated, “I am excited and honored to join Nodality. The team has developed a unique technology platform to create molecular diagnostics for cancer and autoimmune disease, and in partnership with other companies, to improve drug development, enable patient stratification and develop companion diagnostics. Nodality is well-positioned with a broadly talented team, a robust pipeline of molecular diagnostic product opportunities and strong venture investor backing. In addition, the Company has two important ongoing strategic pharma partnerships, which provide strong validation for the SCNP platform. I look forward to the continued success of Nodality and expect to further leverage the Company’s technology and expertise to cultivate additional collaborations that address areas of unmet need.”
Ms. Brege has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., including Executive Vice President and Chief Operating Officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies.
Previously Ms. Brege was SVP and Chief Financial Officer at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the Board of Directors of Acadia Pharmaceuticals, Inc., Delcath Systems, Inc. and Pacira Pharmaceuticals, Inc.
Ms. Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago.
Nodality is a venture-backed, South San Francisco-based personalized medicine biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling (SCNP) technology platform. SCNP enables functional characterization of disease-associated signaling at the individual patient level, enabling optimization of treatment tailored to target the biology driving the disease. Nodality is applying SCNP to develop molecular diagnostics to improve clinical decision-making in cancer and autoimmune diseases, with the lead products targeting treatment management in hematological malignancies. Nodality is also collaborating with Pharma partners on patient stratification & companion diagnostics development, drug & disease profiling, determination of mechanism of action, mechanism-based competitive differentiation, whole blood PD assays, and biomarker discovery & development. These applications can result in increased probability of success, reduced timeline for clinical development, and differentiation from competitors in the marketplace. Nodality established multi-year pharma strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB) and Pfizer (PFE) in February 2012 and August 2012, respectively, in each case utilizing its SCNP technology to assist the development of several compounds focusing initially on immunology disorders.
About Single Cell Network Profiling
Single Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signaling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior at the level of the single cell, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of functional cellular heterogeneity in otherwise molecularly and phenotypically homogeneous tissues, including the identification of rare cell subsets such as drug-resistant and stem cells. As such, the technology has widespread application in both molecular diagnostic development as well as preclinical and clinical drug development.
Daniel Dornbusch, 650-827-8022
Justin Jackson, 212-213-0006